ROCK2 CAPITAL is a global healthcare Long/Short strategy specializing in large pharma, therapeutics, and non-therapeutics which includes tools, MedTech, healthcare IT and diagnostics. 

The market neutral strategy has evolved and been refined over several years focusing on alpha generation on both sides of the book through our strong risk management culture, local and global market fluency and fundamental bottom up stock picking covering all healthcare sub-sectors in the US, Europe and Japan/Australia.

Our objective is to create long term valued partnerships with our LPs while providing superior risk adjusted returns over a multi year period.  

​

Why ROCK2 is unique and important​

ROCK2 is part of a family of enzymes, but its unique importance lies in its specific roles in various diseases, making it a key target for new drug development. Unlike its close relative ROCK1, ROCK2 is predominantly expressed in the brain, heart, and skeletal muscle, and its dysregulation is implicated in a host of conditions from neurodegenerative disorders like Alzheimer's and Parkinson's to cardiovascular diseases, fibrosis, and even cancer metastasis. Inhibiting ROCK2 can prevent cancer cells from spreading and help treat conditions like pulmonary hypertension, highlighting its critical and distinct importance in medicine.

​